Incyclinide
CAS: 15866-90-7
Ref. 3D-QAA86690
5mg | A consultar | ||
10mg | A consultar | ||
25mg | A consultar | ||
50mg | A consultar |
Información del producto
- (4aS,5aR,12aS)-1,4,4a,5,5a,6,11,12a-Octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
- 2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
- 2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4aS,5aR,12aS)-
- 2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, [4aS-(4aα,5aα,12aα)]-
- 4-De(dimethylamino)-6-demethyl-6-deoxytetracycline
- 4-De(dimethylamino)sancycline
- Cmt 3
- Cmt-3,Col-3,Nsc-683551
- Col 3
- Metastat
- Ver más sinónimos
- NSC 683551
Incyclinide is a novel, synthetic, cell permeable, small-molecule antibiotic that exhibits high antibacterial efficacy and has been shown to kill cancer cells. This compound has demonstrated inhibitory properties on the activity of matrix metalloproteinases such as MMP-9. Incyclinide also inhibits the production of proinflammatory cytokines such as TNF-α and IL-1β in human monocytes.
The pharmacokinetics of incyclinide have been studied in humans. The drug is rapidly absorbed with a bioavailability of 100% and reaches peak plasma concentrations within 1 hour after administration. It is excreted unchanged in urine, mainly through glomerular filtration, with an elimination half life of 8 hours.
Propiedades químicas
Consulta técnica sobre: 3D-QAA86690 Incyclinide
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.